Millennium Pharmaceuticals Limited

University of Texas System

Bristol-myers Squibb Compnay

Mayo Foundation for Medical Education and Research

University of California

Bristol-myers Squibb Pharma Company

Edwin A Clark

Robert C Bast

Lynn C Hartmann

Karen Lu

Gordon B Mills

Jeffrey L Brown

Tallessyn Grenfell-Lee

Andrew I Damokosh

Dennis J Slamon

Mark David Ayers

Peter Shaw

Gabriel N Hortobagyi

Xin Huang

Lajos Pusztai

Charles L Ginther

Natalia Iartchouk

Kenneth R Hess

W Fraser Symmans

Shirin K Ford

Hyerim Lee

Jim Stec

Judy Dering

Richard S Finn

James J Stec, Ii

EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.

Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators

The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of 'sensitivity markers.' These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of 'resistance markers.' These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.

Compositions and methods for the identification, assessment, prevention and therapy of human cancers

The invention described herein relates to methods and compositions useful in the diagnosis, treatment and management of cancers that express particular genes, including the moesin, caveolin 1, and/or yes-associated protein 1 genes.

Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers

Biomarkers that are useful for identifying a mammal that will respond therapeutically or is responding therapeutically to a method of treating cancer that comprises administering a microtubule-stabilizing agent. In one aspect, the cancer is breast cancer, and the microtubule-stabilizing agent is an epothilone or analog or derivative thereof, or ixabepilone.

Methods for determining sensitivity to microtubule-stabilizing agents comprising ixabepilone by measuring the level of estrogen receptor 1

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.

Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.

Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer

Growing community of inventors

Pennington, NJ, United States of America

Edwin A Clark